Profile Image

Dr Nikola Bowden

Research Fellow

School of Biomedical Sciences and Pharmacy (Medical Genetics)

Breaking down the barriers

Dr Nikola Bowden uses next-generation genetic profiling techniques to unlock the mysteries of melanoma.

Nikola Bowden in the laboratory 

As a molecular biologist, Dr Nikola Bowden appreciates the importance of scientific process, but as a researcher she has also learnt the value of trusting her instincts. It was a gut feeling that prompted Bowden to pursue a line of research that has consequently shifted the central dogma around the role of DNA repair in melanoma development and provided a possible explanation for why the disease is largely resistant to chemotherapy.

Bowden's breakthrough paper on nucleotide expression repair in melanoma, published in the journal Cancer Research in 2010, was the first to report on the relationship between DNA repair pathways and chemotherapy resistance in melanoma.

"Chemotherapy usually works by attacking the DNA of a cancer cell and damaging it so badly that it dies," Bowden explains. "Normally, the DNA repair pathway in a cell will either fix damage, as it does when we get sunburnt, or 'tell' a cell to die when the damage is extreme. But in melanoma this pathway is dysfunctional, so chemotherapy has little or no effect and the cancerous cells continue to accumulate damage and grow."

Because the same DNA repair pathway fixes damage to cells from sunlight, Bowden is now pursuing a hypothesis that dysfunction in the pathway could increase susceptibility to melanoma. Her research project is supported by the Cure Cancer Australia Foundation and the Hunter Medical Research Institute (HMRI).

"I was surprised to find that no one had pursued this line of research before – it is almost as if it had been dismissed because it was too obvious," Bowden remarks.

The researcher's interest in the DNA repair process was sparked by studies she conducted into the rare childhood skin cancer xeroderma pigmentosum (XP), first as a biomedical science Honours student at the University of Newcastle then later as a postdoctoral research fellow.

"XP sufferers have an inherited mutation in their DNA repair pathway and can develop melanomas from very little exposure to sunlight. There are 12 genes that can carry this mutation and I always suspected that those genes may be involved in adult melanoma as well. So now we are looking at those genes in adults and testing their response to UV light exposure."

Bowden has developed some high-powered international collaborations and counts among her mentors Dr Javed Khan, a leading figure from the US National Cancer Institute. She spent six months at the Institute in 2010, at Khan's invitation, where she learnt 'next-generation' DNA sequencing techniques, which allow her to study the entire human genome at once. She has established an important working relationship with pathologists at the John Hunter Hospital and has contributed her skills in whole genome analysis to collaborations with colleagues investigating a range of diseases including leukaemia, schizophrenia, breast cancer, asthma and multiple sclerosis.

Bowden aims to develop diagnostic tests that will identify people at high risk of melanoma and also assist doctors in predicting how a diagnosed cancer is likely to respond to different drug therapies, so they can tailor patient treatment accordingly. She is already witnessing the benefits of this style of personalised medicine. In one puzzling cancer case, on which she was asked to consult, she was able to determine from DNA testing that a patient had two distinct primary tumours, rather than a primary and a secondary. The finding had important implications for the way the cancer was treated.

"Research can be a long road so it is very encouraging to see that sort of immediate benefit in your work," Bowden says. "I would like to think the genetic analysis we are developing in melanoma will be regularly used in practice within the next five years, so we can give patients a better idea from the outset of the treatment likely to help them most."

Find out more

Nikola Bowden in the laboratory

Breaking down the barriers

Dr Nikola Bowden uses next-generation genetic profiling techniques to unlock the mysteries of melanoma.

Read more

Career Summary

Biography

Dr Nikola Bowden was appointed at the University of Newcastle in 2006 as the inaugural NBN Telethon childhood cancer post-doctoral fellow. Subsequent to this in 2008 she was awarded a Gladys M. Brawn memorial post-doctoral fellowship from the Faculty of Health, University of Newcastle. In January 2009 Dr Bowden was appointed as a Lecturer in the School of Biomedical Sciences & Pharmacy and was awarded an NH&MRC training (post-doctoral) fellowship which she commenced in October 2009. Since 2006, Dr Bowden has developed a research interest with the overall aim of delivering personalised diagnosis and treatment to patients with cancer, with a more focused interest in investigating DNA repair in melanoma. Dr Bowden's research has been funded through a nationally competitive fellowship and grants from the NH&MRC, Cure Cancer Australia Foundation and Cancer Australia, respectively. Dr Bowden collaborates with Dr Daniel Catchpoole at the Children’s Hospital at Westmead and has international collaborations with Prof James Cleaver from University of California San Francisco (USA) and Dr Javed Khan from the National Cancer Institute and National Institutes of Health (USA). Dr Bowden has obtained over $1,000,000 in funding, published 22 articles in international peer-reviewed journals and have presented her research over 60 times at international and national conferences. Dr Bowden currently supervises 4 research higher degree PhD students. Dr Bowden was awarded the University of Newcastle Young Alumni Award in 2011 and was part of a collaboration awarded the Schizophrenia Research Institute Research Paper Award in 2008 and was the recipient of the 2007 Hunter Children's Research Foundation (HCRF) Award for Research Excellence for her research into the DNA repair and skin cancer disorder, Xeroderma Pigmentosum, and childhood acute lymphoblastic leukaemia. In 2006, she was awarded the Hunter Medical Research Institute (HMRI) PULSE Education Prize, an award presented to an outstanding early career researcher. Dr Bowden has been an invited reviewer for the international funding body Medical Research Council (UK), and many international journals.

Research Expertise
Below is a summary of my current research projects: Nucleotide Excision Repair Gene Expression in Melanoma: My main research program is investigating the role of DNA repair in cancer. The results of a pilot study into deficient DNA repair in melanoma have been published in the journal Cancer Research. The publication of this manuscript represents a shift in the central dogma surrounding DNA repair and melanoma. To date there has been a central belief that DNA repair is not involved in development of melanoma. The results of our study have now confirmed the hypothesis that a deficiency in DNA repair is indeed a feature of melanoma and may be the reason why melanomas develop after excessive sun exposure and why melanomas do not respond to common chemotherapeutic agents. The major outcome of this research program will be a biological explanation for why excessive sunlight exposure results in melanomagenesis and why melanomas do not respond to common DNA-damaging chemotherapeutic agents, two of the most elusive features of melanoma. In addition, I collaborate with Dr Ricardo Vilain and Dr Stephen Braye from the Hunter Area Pathology Service (HAPS) Anatomocal Pathology department to utilise formalin-fixed paraffin embedded (FFPE) melanoma tissue collected and stored for diagnostic purposes. This tissue represents a very large cohort of individuals from the hunter region with melanoma and allows for retrospective analysis of clinical data such as disease recurrence, response to treatment and survival. Another major advantage of using this tissue is that it requires no direct participation from patients with melanoma thus lessening the burden of research on clinicians and patients. This collaboration was established in 2009 and the preliminary results of several projects have been presented at the 7th and 8th International Congress of the Society for Melanoma Research (2010 & 2011).

Teaching Expertise
The following is a summary of my major research training and teaching: • Currently primary supervisor of 4 PhD students, co-supervisor of 3 PhD students. Previously supervised 3 !st Class Honours students. • Supervised B. Biomedical Science 3rd year HUBS3409 students to undertake research project (2009 & 2011) • Delivered the lectures and tutorials for the genetics and genomics component of the M. Pharmacy course PHAR6123 – Human Genomics and Biomolecular Analysis (2005, 2006, 2008, 2011, 2013) • Delivered 6 lectures for B. Biomedical Science HUBS2409 Bioinformatics and Functional Genomics in 2008 and annual guest lectures in 2005-2006. 


Qualifications

  • PhD, University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Chemotherapy
  • DNA repair
  • Genetics
  • Melanoma
  • UV-light

Fields of Research

CodeDescriptionPercentage
060199Biochemistry and Cell Biology not elsewhere classified50
111299Oncology and Carcinogenesis not elsewhere classified50

Professional Experience

UON Appointment

DatesTitleOrganisation / Department
1/01/2015 - 31/12/2017Research FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
14/07/2008 - 31/12/2008Casual AcademicUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

DatesTitleOrganisation / Department
1/10/2009 - Post-Doctoral FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/09/2009 - 1/12/2014FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2009 - 1/10/2009LecturerUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2008 - 1/12/2008Postdoctoral Fellow - Gladys M. Brawn Memorial University of Newcastle
Australia
1/01/2006 - 1/12/2007NBN Telethon Postdoctoral FellowUniversity of Newcastle
Hunter Medical Research Institute
Australia
1/01/2006 - 1/12/2008Post-Doctoral FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Membership

DatesTitleOrganisation / Department
1/01/2012 - Membership - NHMRC Post-Doctoral Reference GroupThe NHMRC Postdoctoral Reference Group
Australia
1/01/2012 - Membership - NHMRC Research Translation FacultyNHMRC Research Translation Faculty
Australia
1/01/2010 - Membership - Society for Melanoma ResearchSociety for Melanoma Research
Australia
1/01/2008 - Membership - American Association of Cancer ResearchAmerican Association of Cancer Research
United States
1/01/2006 - Membership - Australian Society of Medical ResearchAustralian Society of Medical Research
Australia

Awards

Recipient

YearAward
2011Young Alumni Award
University of Newcastle

Recognition

YearAward
2012Emerging Research Leaders Program
University of Newcastle
2007INSIGHT
Hunter Medical Research Institute

Research Award

YearAward
2007Award for Research Excellence
Hunter Medical Research Institute (HMRI)
2006PULSE Education Prize
Hunter Medical Research Institute
2006Student Support Award to attend the International Congress on
Human Genetics Society of Australasia (HGSA)
2004Student Travel Award
International Society of Psychiatric Genetics
2003Student Travel Award
Australasian Neuroscience Society
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (29 outputs)

YearCitationAltmetricsLink
2014Evans TJ, Milne E, Anderson D, de Klerk NH, Jamieson SE, Talseth-Palmer BA, et al., 'Confirmation of childhood acute lymphoblastic leukemia variants, ARID5B and IKZF1, and interaction with parental environmental exposures.', PLoS One, 9 e110255 (2014) [C1]
DOI10.1371/journal.pone.0110255Author URL
CitationsScopus - 1Web of Science - 1
Co-authorsJohn Attia, Rodney Scott, Bente Talseth-Palmer, Liz Holliday
2014Ashton KA, Scurry J, Ouveysi A, Ebbs J, Jaaback K, Bowden NA, 'Transformation of endometrioid carcinoma to carcinoma with trophoblastic differentiation: clinicopathological and whole genomic study.', Pathology, 46 351-353 (2014) [C3]
DOI10.1097/PAT.0000000000000101Author URL
Co-authorsKatie Ashton
2014Wong-Brown MW, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer', International Journal of Cancer, 134 301-305 (2014) [C1]

Triple-negative breast cancer (TNBC) is a tumour classification that is defined by oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 receptor negativity. TNBCs share a similar gene expression profile to BRCA-mutated tumours, have been shown to carry a high proportion of BRCA mutations and have a more adverse prognosis compared to other types of breast tumours. PALB2 has been shown to be a moderate-penetrance breast cancer susceptibility gene and is involved in the same DNA damage repair pathway as BRCA1 and BRCA2; this raises the possibility that germline PALB2 mutations may be involved in the pathogenesis of TNBCs. In our study, we sequenced the coding regions of PALB2 (including intron/exon boundaries) in genomic DNA from 347 patients diagnosed with TNBC to determine the prevalence of deleterious mutations in this population. Two novel truncating mutations (c.758dup and c.2390del) and one previously detected truncating mutation (c.3113+5G>C) were found. In addition, five variants predicted to be protein-affecting were also identified. Our study shows that the prevalence of PALB2 germline mutations in individuals with TNBC is ~1%, similar to the prevalence of PALB2 germline mutation of 1% in familial non-BRCA1/2 breast cancer cohorts. © 2013 UICC.

DOI10.1002/ijc.28361
CitationsScopus - 1
Co-authorsKelly Kiejda, Michelle Wong-Brown, Rodney Scott
2014Bowden NA, 'Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?', Cancer Letters, (2014) [C1]

Platinum based therapy is one of the most effectively used chemotherapeutic treatments for cancer. The mechanism of action of platinum compounds is to damage DNA and drive cells into apoptosis. The most commonly used platinum containing agents are cis-diammine-dichloroplatinum (II)], more commonly known as cisplatin, its analogue carboplatin, and oxaliplatin. Cisplatin is used to treat a wide variety of tumours such as ovarian, testicular, head and neck and non-small cell lung cancers (NSCLCs). In addition, it forms the basis of most combined treatment regimes. Despite this, cisplatin and its analogues are extremely toxic and although some patients benefit substantially from treatment, a large proportion suffer the toxic side effects without any therapeutic benefit. Nucleotide excision repair (NER) is a versatile DNA repair system that recognises DNA damage induced by platinum based therapy. For many years the components of the NER pathway have been studied to determine mRNA and protein expression levels in response or resistance to cisplatin in many forms of cancer; particularly testicular, ovarian and NSCLCs. Despite the consistent finding that over or under expression of subsets of NER proteins and mRNA highly correlate with response to cisplatin, the translation of these findings into the clinical setting has not been forthcoming. This review summarises the results of previous investigations into NER in cisplatin response and clinical trials where the expression of NER proteins were compared to the response to platinum therapies in treatment. © 2014 Elsevier Ireland Ltd. All rights reserved.

DOI10.1016/j.canlet.2014.01.005
CitationsScopus - 9Web of Science - 10
2014Wan C, Latter JL, Amirshahi A, Symonds I, Finnie J, Bowden N, et al., 'Progesterone Activates Multiple Innate Immune Pathways in Chlamydia trachomatis-Infected Endocervical Cells', American Journal of Reproductive Immunology, 71 165-177 (2014)
DOI10.1111/aji.12168
CitationsScopus - 1
Co-authorsJoanna Latter, Ian Symonds, Rodney Scott
2014Wan C, Latter JL, Amirshahi A, Symonds I, Finnie J, Bowden N, et al., 'Progesterone Activates Multiple Innate Immune Pathways in Chlamydia trachomatis-Infected Endocervical Cells', American Journal of Reproductive Immunology, 71 165-177 (2014) [C1]

Problem: Susceptibility to Chlamydia trachomatis infection is increased by oral contraceptives and modulated by sex hormones. We therefore sought to determine the effects of female sex hormones on the innate immune response to C. trachomatis infection. Method of study: ECC-1 endometrial cells, pre-treated with oestradiol or progesterone, were infected with C. trachomatis and the host transcriptome analysed by Illumina Sentrix HumanRef-8 microarray. Primary endocervical epithelial cells, prepared at either the proliferative or secretory phase of the menstrual cycle, were infected with C. trachomatis and cytokine gene expression determined by quantitative RT-PCR analysis. Results: Chlamydia trachomatis yield from progesterone-primed ECC-1 cells was significantly reduced compared with oestradiol-treated cells. Genes upregulated in progesterone-treated and Chlamydia-infected cells only included multiple CC and CXC chemokines, IL-17C, IL-29, IL-32, TNF-a, DEFB4B, LCN2, S100A7-9, ITGAM, NOD2, JAK1, IL-6ST, type I and II interferon receptors, numerous interferon-stimulated genes and STAT6. CXCL10, CXCL11, CX3CL1 and IL-17C, which were also upregulated in infected secretory-stage primary cells, and there was a trend towards higher levels of immune mediators in infected secretory-phase compared with proliferative-phase cells. Conclusion: Progesterone treatment primes multiple innate immune pathways in hormone-responsive epithelial cells that could potentially increase resistance to chlamydial infection. © 2013 John Wiley & Sons Ltd.

DOI10.1111/aji.12168
CitationsScopus - 1Web of Science - 2
Co-authorsRodney Scott, Joanna Latter, Ian Symonds
2014Cox MB, Bowden NA, Scott RJ, Lechner-Scott J, 'Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis', Multiple Sclerosis Journal, 20 489-491 (2014) [C1]

Matrix metalloproteinase 9 (MMP9) is involved in multiple sclerosis (MS) aetiology. Previously, we identified differential gene expression of plasminogen activation cascade genes in MS patients. Based on our gene expression results, we wanted to identify whether polymorphisms in the genes associated with the plasminogen pathway could predict MS risk. We genotyped 1153 trio families, 727 MS cases and 604 healthy controls for 17 polymorphisms in MMP9, plasminogen activator urokinase (PLAU), PLAU receptor (PLAUR) and serpin peptidase inhibitor/clade 2/member B2 (SERPINB2) genes. No associations were found between the 17 polymorphisms and MS. Also, gene expression levels were analysed according to genotype: no associations were observed. In conclusion despite the consistent evidence for the role of MMP9 and the plasminogen activation cascade in MS, we found no associations between genotype nor gene expression. This suggested there are other potentially modifiable factors influencing gene expression in MS. © The Author(s) 2013.

DOI10.1177/1352458513498127
CitationsScopus - 1Web of Science - 1
Co-authorsRodney Scott
2013Cox MB, Bowden NA, Scott RJ, Lechner-Scott J, 'Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation', Multiple Sclerosis Journal, 19 1268-1274 (2013) [C1]
DOI10.1177/1352458513475493Author URL
CitationsScopus - 1Web of Science - 1
Co-authorsRodney Scott
2013Budden T, Bowden NA, 'The Role of Altered Nucleotide Excision Repair and UVB-Induced DNA Damage in Melanomagenesis', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 14 1132-1151 (2013) [C1]
DOI10.3390/ijms14011132Author URL
CitationsScopus - 15Web of Science - 17
2013Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Avery-Kiejda KA, Scott RJ, 'STaRRRT: a table of short tandem repeats in regulatory regions of the human genome', BMC GENOMICS, 14 (2013) [C1]
DOI10.1186/1471-2164-14-795Author URL
CitationsScopus - 4Web of Science - 5
Co-authorsRodney Scott, Liz Holliday, Kelly Kiejda
2013Bowden NA, Ashton KA, Vilain RE, Avery-Kiejda KA, Davey RJ, Murray HC, et al., 'Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma', PLOS ONE, 8 (2013) [C1]
DOI10.1371/journal.pone.0070424Author URL
CitationsScopus - 1Web of Science - 1
Co-authorsKelly Kiejda, Rodney Scott, Katie Ashton, Xu Zhang
2012Ashton KA, Scurry JP, Rutherford J, Otton GR, Scott R, Bowden NA, 'Nodular prurigo of the vulva', Pathology, 44 565-567 (2012) [C3]
CitationsScopus - 1Web of Science - 1
Co-authorsRodney Scott, Katie Ashton
2012Young KMN, Scurry JP, Jaaback KS, Bowden NA, Scott R, 'Bilateral dysgerminoma associated with gonadoblastoma and sex-cord stromal tumour with annular tubules in a 28-year-old fertile woman with normal karyotype', Pathology, 44 257-260 (2012) [C3]
CitationsScopus - 2Web of Science - 2
Co-authorsRodney Scott
2012Cox MB, Ban M, Bowden NA, Baker A, Scott R, Lechner-Scott J, 'Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis', Multiple Sclerosis Journal, 18 16-22 (2012) [C1]
CitationsScopus - 22Web of Science - 21
Co-authorsRodney Scott
2011Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al., 'P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation', BMC Cancer, 11 203-219 (2011) [C1]
DOI10.1186/1471-2407-11-203
CitationsScopus - 28Web of Science - 21
Co-authorsKatie Ashton, Bente Talseth-Palmer, Kelly Kiejda, Rodney Scott, Xu Zhang
2011Wong-Brown M, Nordfors C, Mossman D, Pecenpetelovska G, Kiejda KA, Talseth-Palmer B, et al., 'BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer', Breast Cancer Research and Treatment, 127 853-859 (2011) [C1]
DOI10.1007/s10549-011-1443-0
CitationsScopus - 39Web of Science - 37
Co-authorsRodney Scott, Kelly Kiejda, Bente Talseth-Palmer, Michelle Wong-Brown
2010Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Nucleotide excision repair gene expression after cisplatin treatment in melanoma', Cancer Research, 70 7918-7926 (2010) [C1]
CitationsScopus - 8Web of Science - 7
Co-authorsRodney Scott, Kelly Kiejda, Katie Ashton, Xu Zhang
2010Li J, Wang W, Baines KJ, Bowden NA, Hansbro PM, Gibson PG, et al., 'IL-27/IFN-y induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages', Journal of Immunology, 185 4401-4409 (2010) [C1]
DOI10.4049/jimmunol.1001039
CitationsScopus - 35Web of Science - 32
Co-authorsPaul Foster, Peter Gibson, Philip Hansbro, Ming Yang, Katherine Baines
2010Baines KJ, Simpson JL, Bowden NA, Scott R, Gibson PG, 'Differential gene expression and cytokine production from neutrophils in asthma phenotypes', European Respiratory Journal, 35 522-531 (2010) [C1]
DOI10.1183/09031936.00027409
CitationsScopus - 30Web of Science - 24
Co-authorsRodney Scott, Peter Gibson, Jodie Simpson, Katherine Baines
2009Talseth-Palmer B, Bowden NA, Meldrum C, Nicholl J, Thompson E, Friend K, et al., 'A 1q44 deletion, paternal UPD of chromosome 2 and a deletion due to a complex translocation detected in children with abnormal phenotypes using new SNP array technology', Cytogenetic and Genome Research, 124 94-101 (2009) [C1]
DOI10.1159/000200093
CitationsScopus - 4Web of Science - 4
Co-authorsBente Talseth-Palmer, Rodney Scott
2008Bowden NA, Scott R, Tooney PA, 'Altered gene expression in the superior temporal gyrus in schizophrenia', BMC Genomics, 9 1-12 (2008) [C1]
DOI10.1186/1471-2164-9-199
CitationsScopus - 32Web of Science - 32
Co-authorsPaul Tooney, Rodney Scott
2008Talseth-Palmer B, Bowden NA, Hill A, Meldrum C, Scott R, 'Whole genome amplification and its impact on CGH array profiles', BMC Research Notes, 1 108 (2008) [C1]
DOI10.1186/1756-0500-1-56
CitationsScopus - 11
Co-authorsBente Talseth-Palmer, Rodney Scott
2008Beveridge NJ, Tooney PA, Carroll AP, Gardiner EJ, Bowden NA, Scott R, et al., 'Dysregulation of miRNA 181b in the temporal cortex in schizophrenia', Human Molecular Genetics, 17 1156-1168 (2008) [C1]
DOI10.1093/hmg/ddn005
CitationsScopus - 166Web of Science - 161
Co-authorsRodney Scott, Murray Cairns, Paul Tooney
2007Bowden NA, Scott R, Tooney PA, 'Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia', Schizophrenia Research, 89 165-168 (2007) [C1]
DOI10.1016/j.schres.2006.09.003
CitationsScopus - 33Web of Science - 36
Co-authorsPaul Tooney, Rodney Scott
2007Bowden NA, Croft A, Scott R, 'Gene expression profiling in familial adenomatous polyposis adenomas and desmoid disease', Hereditary Cancer in Clinical Practice, 5 79-96 (2007) [C1]
DOI10.1186/1897-4287-5-2-79
CitationsScopus - 4Web of Science - 4
Co-authorsRodney Scott
2006Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Altered gene expression in the amygdala in schizophrenia: Up-regulation of genes located in the cytomatrix active zone', Molecular and Cellular Neuroscience, 31 243-250 (2006) [C1]
DOI10.1016/j.mcn.2005.09.013
CitationsScopus - 34Web of Science - 34
Co-authorsPaul Tooney, Judith Weidenhofer, Rodney Scott
2006Bowden NA, Weidenhofer JC, Scott R, Schall U, Todd J, Michie PT, Tooney PA, 'Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia', Schizophrenia Research, 82 175-183 (2006) [C1]
DOI10.1016/j.schres.2005.11.012
CitationsScopus - 77Web of Science - 67
Co-authorsUlrich Schall, Rodney Scott, Judith Weidenhofer, Pat Michie, Paul Tooney, Juanita Todd
2006Bowden NA, Tooney PA, Scott R, 'Gene expression profiling of xeroderma pigmentosum', Hereditary Cancer in Clinical Practice, 4 103-110 (2006) [C1]
DOI10.1186/1897-4287-4-2-103
CitationsScopus - 1
Co-authorsPaul Tooney, Rodney Scott
2006Weidenhofer J, Bowden NA, Scott RJ, Tooney PA, 'Dysfunction of genes regulating membrane exocytosis in schizophrenia', AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 40 A129-A129 (2006)
Author URL
Co-authorsPaul Tooney, Rodney Scott, Judith Weidenhofer
Show 26 more journal articles

Conference (72 outputs)

YearCitationAltmetricsLink
2014Warren CFA, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'Association of BCL-2B expression with increased survival and response to stress in melanoma suggests a functional role for this previously uncharacterised isoform.', Keystone Symposia on Molecular and Cellular Biology, Sao Paulo, Brazil (2014) [E3]
Co-authorsKatie Ashton, Pablo Moscato
2014Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Avery-Kiejda KA, Scott RJ, 'Short tandem repeats are variable genetic elements that may have major consequences for multiple diseases.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme, Newcastle, NSW, Australia (2014)
Co-authorsRodney Scott, Liz Holliday, Kelly Kiejda
2014Bowden NA, 'Overcoming chemoresistance in melanoma and ovarian cancer.', Proceedings of the Inaugural EMBL Australia PhD Symposium, Sydney, NSW, Australia (2014) [E3]
2014Warren CFA, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'A functional role in cellular stress response and melanoma pathology for the previously uncharacterised isoform, Bcl-2B.', Proceedings of the Inaugural EMBL Australia PhD Symposium, Sydney, NSW, Australia (2014) [E3]
Co-authorsKatie Ashton, Pablo Moscato
2014Budden T, Davey RJ, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'Repair of UVB-induced DNA damage is reduced in melanoma due to attenuated XPC and global genome repair.', Proceedings of the Inaugural EMBL Australia PhD Symposium, Sydney, NSW, Australia (2014) [E3]
Co-authorsRodney Scott, Katie Ashton
2014Bowden NA, 'How melanoma and melanocytes respond to UV-light and chemotherapy', Skin Cancer College of Australasia, Surfers Paradise, Qld, Australia (2014) [E3]
2014Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Kiejda KA, Scott RJ, 'Short tandem repeats are variable genetic elements that may have major consequences for multiple diseases.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting Programme, Newcastle, NSW, Australia (2014) [E3]
Co-authorsRodney Scott, Kelly Kiejda, Liz Holliday
2014Budden T, Bowden NA, 'GLOBAL DEMETHYLATION CAN RESTORE XPC EXPRESSION AND OVERCOME PLATINUM THERAPY RESISTANCE IN MELANOMA IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
2014Bolton KA, Holliday EG, McEvoy M, Attia J, Proietto A, Otton G, et al., 'A HIGHLY POLYMORPHIC AG REPEAT IN THE UPSTREAM REGULATORY REGION OF THE ESTROGEN-INDUCED GENE EIG121 IS A POTENTIAL MODIFIER OF ENDOMETRIAL CANCER RISK', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsLiz Holliday, Kelly Kiejda, Rodney Scott, John Attia
2014Davey RJ, Budden T, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'REPAIR OF UVB-INDUCED DNA DAMAGE IS REDUCED IN MELANOMA DUE TO ATTENUATED XPC AND GLOBAL GENOME REPAIR', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsRodney Scott, Katie Ashton
2014Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'A FUNCTIONAL ROLE IN MELANOMA PATHOLOGY AND CELLULAR RESPONSE TO STRESS FOR THE PREVIOUSLY UNCHARACTERISED ISOFORM, BCL2B', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsPablo Moscato, Katie Ashton
2014Murray HC, Maltby VE, Bowden NA, 'Nucleotide excision repair in response to UVA is deficient in melanoma.', Pigment Cell and Melanoma Research, Singapore (2014) [E3]
DOI10.1111/pcmr.12292
Co-authorsVicki E Maltby
2014Budden T, Bowden NA, 'Melanoma exhibits defective nucleotide excision repair of UVB-induced DNA photoproducts', Pigment Cell and Melanoma Research, Singapore (2014) [E3]
DOI10.1111/pcmr.12292
2014Bolton KA, Holliday EG, Bowden NA, Avery-Kiejda KA, Scott RJ, 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is a modifier of disease risk in endometrial cancer', EUROPEAN JOURNAL OF CANCER (2014) [E3]
Author URL
Co-authorsKelly Kiejda, Rodney Scott, Liz Holliday
2014Bolton KA, Ross JP, Grice DM, Bowden NA, Holliday EG, Avery-Kiejda KA, Scott RJ, 'Short tandem repeats are variable genetic elements that may have major consequences for multiple disease.', ASMR Satellite Scientific Meeting Proceedings, Newcastle, NSW, Australia (2014)
2014Davey RJ, Vilain RE, Ashton KA, Braye SG, Scott RJ, Bowden NA, 'XPC expression is associated with BRAFV600E and NRASQ61R mutations and poor survival in melanoma.', ASMR Satellite scientific meeting proceedings, Newcastle, NSW, Australia (2014) [E3]
Co-authorsKatie Ashton, Rodney Scott
2014Murray HC, Maltby VE, Bowden NA, 'Nucleotide excision repair function in melanoma.', ASMR Satellite scientific meeting proceedings, Newcastle, NSW, Australia (2014) [E3]
2014Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'The expression of the previously uncharacterised isoform, Bcl-2B is associated with increased survival in melanoma.', ASMR Satellite scientific meeting proceedings, Newcastle, NSW, Australia (2014) [E3]
Co-authorsPablo Moscato, Katie Ashton
2014Budden T, Bowden NA, 'Melanoma displays reduced nucleotide excision repair in response to UVB-induced DNA damage', ASMR Scientific Satellite Meeting Proceedings, Newcastle, NSW, Australia (2014) [E3]
2014Bolton KA, Holliday EG, McEvoy M, Attia J, Proietto A, Otton G, et al., 'A highly polymorphic AG repeat in the upstream regulatory region of the estrogen gene EIG121 is a potential modifier of endometrial cancer risk.', Asia-Pacific Journal of Clinical Oncology, Newcastle, NSW, Australia (2014) [E3]
DOI10.1111/ajco.12335
Co-authorsLiz Holliday, Rodney Scott, Kelly Kiejda, John Attia
2014Bowden NA, 'Investigation of the nucleotide excision repair pathway for melanoma biomarkers', Cure Cancer Australia symposium proceedings, Sydney, NSW, Australia (2014) [E3]
2013Bolton KA, Ross J, Grice DM, Avery-Kiejda KA, Bowden NA, Holliday EG, Scott RJ, 'Role of Short Tandem Repeats in Disease and Evolutionary Mechanisms.', 34th Lorne Genome Conference Proceedings, Lorne, VIC, Australia (2013) [E3]
Co-authorsRodney Scott, Kelly Kiejda, Liz Holliday
2013Davey RJ, Ashton KA, Vilain RE, Braye SG, Scott RJ, Bowden NA, 'Nucleotide excision repair: biomarkers of UV-radiation and disease progression in melanoma.', HMRI Translational Cancer Research Conference, Newcastle, NSW, Australia (2013)
2013Budden T, Scott RJ, Bowden NA, 'Altered nucleotide excision repair in melanoma in response to UVB-induced DNA damage.', HMRI Translational Cancer Research Conference, Newcastle, NSW, Australia (2013)
2013Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'Expression of the alternatively spliced variants of Bcl-2 in melanoma', HMRI Translational Cancer Research Conference, Newcastle, NSW, Australia (2013)
2013Ashton KA, Davey RJ, Vilain RE, Braye SG, Scott RJ, Bowden NA, 'Investigation of UV radiation, clinical data and the transcriptome of diagnostic melanoma tissue.', HMRI Translational Cancer Research Conference, Newcastle, NSW, Australia (2013)
2013Murray HC, Maltby VE, Bowden NA, 'Deficient expression of global genome nucleotide excision repair genes in melanoma cells following UVA irradiation.', HMRI Translational Cancer Research Conference, Newcastle, NSW, Australia (2013)
2013Wong-Brown M, Li S, Wilkins M, Avery-Kiejda KA, Bowden N, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in familial breast cancer.', Kathleen Cunningham Foundation Consortium for Research into Familial Aspects of Cancer 2013 Research and Practice Proceedings, Cairns, QLD, Australia. (2013) [E3]
Co-authorsMichelle Wong-Brown, Rodney Scott, Kelly Kiejda
2013Wong-Brown M, Avery-Kiejda K, Bowden N, Scott R, 'Prevalence of BRCA1 and BRCA2 germline mutations in triple-negative breast cancer', Programme, Newcastle (2013) [E3]
CitationsWeb of Science - 1
Co-authorsMichelle Wong-Brown, Rodney Scott, Kelly Kiejda
2013Bolton KA, Avery-Kiejda KA, Grice DM, Holliday EG, Bowden NA, Ross J, Scott RJ, 'STaRRRT: Our new resource for identifying candidates of genetic risk in breast and endometrial cancer.', Translational Cancer Research Conference Abstract booklet, Newcastle, Australia (2013) [E3]
Co-authorsLiz Holliday, Rodney Scott, Kelly Kiejda
2013Ashton KA, Vilain RE, Braye SG, Scott RJ, Bowden NA, 'Investigation of clinical parameters and altered transcriptome expression associated with UV radiation in melanoma.', Pigment Cell and Melanoma Research, Philadelphia, USA (2013)
DOI10.1111/pcmr.12166
2013Murray HC, Maltby VE, Bowden NA, 'Nucleotide Excision Repair of UVA-Induced DNA Damage: Function in Sunlight-Induced Melanoma.', Pigment Cell and Melanoma Research, Philadelphia, USA (2013)
DOI10.1111/pcmr.12166
2013Warren C, Ashton KA, Vilain RE, Braye SG, Moscato P, Bowden NA, 'Expression of the uncharacterised Bcl-2 isoform, Bcl-2ß, in melanoma.', Pigment Cell and Melanoma Research, Philadelphia, USA (2013)
DOI10.1111/pcmr.12166
2013Davey RJ, Ashton KA, Vilain RE, Braye SG, Scott RJ, Bowden NA, 'Investigation of the nucleotide excision repair pathway for biomarkers of UV-radiation and disease progression in melanoma.', Pigment Cell and Melanoma Research, Philadelphia, USA (2013)
DOI10.1111/pcmr.12166
2013Budden T, Scott RJ, Bowden NA, 'Possible Role for Nucleotide Excision Repair and UVB-induced DNA damage in Melanoma Development', Pigment Cell and Melanoma Research, Philadelphia, USA (2013)
DOI10.1111/pcmr.12166
2012Bowden NA, Ashton K, Vilian R, Braye S, Scott R, 'DNA repair transcripts: biomarkers of sun exposure and tumour aggression in melanoma', Abstract book, Sydney (2012) [E3]
2012Bolton KA, Ross J, Grice DM, Kiejda KA, Bowden NA, Holliday EG, Scott R, 'Potential role of short tandem repeats in disease processes', Abstracts. 6th Australian Health & Medical Research Congress, Adelaide, SA (2012) [E3]
Co-authorsRodney Scott, Kelly Kiejda, Liz Holliday
2012Bowden NA, Ashton KA, Vilain RE, Braye SG, Avery-Kiejda KA, Zhang XD, et al., 'Regulators of DNA repair do not respond to DNA damaging therapy but correlate with survival in melanoma.', Biomarker Discovery Conference Proceedings, Shoal Bay, NSW, Australia (2012)
2012Bowden NA, 'Utilisation of personal CNV for diagnosis and treatment of cancer - A discussion of 2 cases in a clinical setting', Biomarker Discovery Conference Proceedings, Shoal Bay, NSW, Australia (2012)
2012Wong M, Avery-Kiejda KA, Bowden NA, Scott RJ, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Human Genome Meeting, Sydney, NSW, Australia (2012)
2012Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Exploratory targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Programme. kConFab Familial Aspects of Cancer: Research & Practice 2012, Kingscliff, NSW (2012) [E3]
Co-authorsRodney Scott, Michelle Wong-Brown, Kelly Kiejda
2012Wong-Brown M, Li S, Wilkins M, Kiejda KA, Bowden NA, Scott R, 'Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer', Cancer Research, San Antonio, Texas (2012) [E3]
Co-authorsRodney Scott, Kelly Kiejda, Michelle Wong-Brown
2011Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Downstream effects of reduction in nucleotide excision repair in response to cisplatin treatment in melanoma', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
DOI10.1111/j.1755-148X.2011.00909.x
Co-authorsXu Zhang, Rodney Scott, Kelly Kiejda, Katie Ashton
2011Johansson P, Wei JS, Chen Q, Bowden NA, Badgett TC, Song YK, et al., 'A genomic portrait of tumor progression using next-generation sequencing', American Association for Cancer Research (AACR) 102nd Annual Meeting. Innovation and Collaboration: The Path to Progress Proceedings, Orlando, FL (2011) [E3]
2011Foster P, Li J, Wang W, Baines K, Bowden N, Hansbro P, et al., 'IL-27 underpins steroid resistant airway hyperresponsiveness via MyD88 dependent pathways', ALLERGY, Istanbul, TURKEY (2011) [E3]
Author URL
Co-authorsPhilip Hansbro
2010Croft AJ, Kiejda KA, Bowden NA, Zhang X, Scott R, Hersey P, 'Expression profiling on apoptosis-related genes in cisplatin-treated human melanoma cell lines', 22nd Lorne Cancer Conference: Abstracts and Delegate Information, Lorne, Vic. (2010) [E3]
Co-authorsKelly Kiejda, Rodney Scott
2010Wong-Brown M, Bowden NA, Kiejda KA, Scott R, 'BRIP1 and PALB2 mutation detection in Hunter-New England familial breast cancer cohort', 27th HUGO-IABCR Congress 2010. Genomics, Biology and Breast Cancer Treatment. Programme & Abstract Book, Biopolis, Singapore (2010) [E3]
Co-authorsMichelle Wong-Brown, Rodney Scott, Kelly Kiejda
2010Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
DOI10.1158/0008-5472.CAN-10-0161
Co-authorsKelly Kiejda, Rodney Scott, Xu Zhang, Katie Ashton
2010Ashton KA, Bowden NA, Kairupan CF, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Base excision repair and gene expression profiling in malignant melanoma', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authorsKelly Kiejda, Rodney Scott, Katie Ashton, Xu Zhang
2010Wong-Brown M, Bowden NA, Forbes JF, Braye SG, Scott R, 'Microsatellite instability (I) in breast tumours', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authorsJohn Forbes, Rodney Scott, Michelle Wong-Brown
2010Ashton KA, Bowden NA, Vilain RE, Kairupan CF, Kiejda KA, Zhang XD, et al., 'Genetic variation of the base excision repair gene, MUTYH, and melanoma development', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
Co-authorsKatie Ashton, Xu Zhang, Kelly Kiejda
2010Bowden NA, Ashton KA, Kiejda KA, Vilain RE, Braye SG, Kairupan CF, et al., 'Nucleotide excision repair gene expression in melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
DOI10.1158/0008-5472.CAN-10-0161
Co-authorsXu Zhang, Katie Ashton, Kelly Kiejda
2010Vilain RE, Ashton KA, Bowden NA, Braye SG, Ashman LK, Scott RJ, 'Clinicopathological and gene expression profiling of advanced melanoma harbouring KIT and common kinase mutations', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
Co-authorsKatie Ashton, Leonie Ashman
2009Kiejda KA, Scurr LL, Wade MA, Jiang CC, Weir AJW, Bowden NA, et al., 'Cisplatin induces apoptosis independently of Noxa or PUMA in human melanoma cells', 21st Lorne Cancer Conference, Lorne, VIC (2009) [E3]
Co-authorsRodney Scott, Kelly Kiejda, Xu Zhang
2009Cox MB, Bowden NA, Scott R, Lechner-Scott J, 'Gene expression profiling in multiple sclerosis', AMATA 2009, Katoomba, NSW (2009) [E3]
Co-authorsRodney Scott
2009Evans T-J, Bowden NA, Talseth-Palmer B, Catchpoole D, Scott R, 'Copy number variation in childhood acute lmphoblastic leukaemia', AMATA 2009, Katoomba, NSW (2009) [E3]
Co-authorsRodney Scott, Bente Talseth-Palmer
2009Bowden NA, Ashton KA, Stibbard GJ, Cox MB, Baines KJ, Scott R, 'Predicting xeroderma pigmentosum complementation group by gene expression profiling', AMATA 2009, Katoomba, NSW (2009) [E3]
Co-authorsKatherine Baines, Rodney Scott, Katie Ashton
2009Kairupan CF, Bowden NA, Ashton KA, Zhang XD, Hersey P, Scott R, 'Gene expression profiling in malignant melanoma', AMATA 2009, Katoomba, NSW (2009) [E3]
Co-authorsRodney Scott, Katie Ashton, Xu Zhang
2008Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', Proceedings of the Australian Health and Medical Research Congress 2008, Brisbane, QLD (2008) [E3]
Co-authorsKatie Ashton, Kelly Kiejda, Xu Zhang, Rodney Scott
2008Bowden NA, Baines KJ, Cox MB, Scott R, 'Altered gene expression in nucleotide excision repair deficient fibroblasts after UV-light exposure', AACR Meeting Abstracts, San Diego, CA (2008) [E3]
Co-authorsRodney Scott, Katherine Baines
2008Bowden NA, Baines KJ, Cox MB, Scott R, 'Response to uv-light exposure in fibroblasts with differential nucleotide excision repair capacity', ASMR XVII NSW Scientific Meeting: Programme and Abstracts, Sydney, NSW (2008) [E3]
Co-authorsKatherine Baines, Rodney Scott
2008Bowden NA, Ashton KA, Baines KJ, Cox MB, Scott R, 'Altered gene expression after UV-light induced DNA damage', Conference on Translational Cancer Research: Abstracts, Newcastle, NSW (2008) [E3]
Co-authorsKatherine Baines, Katie Ashton, Rodney Scott
2007Baines KJ, Bowden NA, Scott R, Simpson JL, Gibson PG, 'Molecular analysis of neutrophils in asthma subtypes', Respirology (TSANZ Abstracts-Posters), Auckland (2007) [E3]
DOI10.1111/j.1440-1843.2007.001050.x
Co-authorsJodie Simpson, Peter Gibson, Rodney Scott, Katherine Baines
2007Cox M, Bowden NA, Moscato PA, Berretta RE, Scott R, 'Memetic algorithms as a new method to interpret gene expression profiles in multiple sclerosis', Multiple Sclerosis (Abstracts of the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 12th Annual Conference of Rehabilitation in Multiple Sclerosis), Prague, Czech Republic (2007) [E3]
CitationsWeb of Science - 2
Co-authorsPablo Moscato, Rodney Scott, Regina Berretta
2007Tooney PA, Scott R, Cairns MJ, Bowden NA, 'Altered gene expression in the superior temporial gyrus in schizophrenia', Schizophrenia Bulletin (Abstracts of the 11th International Congress on Schizophrenia Research), Colorado Springs, Colorado (2007) [E3]
Co-authorsPaul Tooney, Murray Cairns, Rodney Scott
2006Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Dysfunction of genes regulating membrane exocytosis in schizophrenia (Poster presentation)', Australian and New Zealand Journal of Psychiatry (Vol 40, noS2), Fremantle, Western Australia (2006) [E3]
Co-authorsPaul Tooney, Judith Weidenhofer, Rodney Scott
2005Bowden NA, Weidenhofer JC, Scott R, Schall UA, Todd J, Michie PT, Tooney PA, 'Classification of schizophrenia using differential gene expression in peripheral blood lymphocytes', Human Genetics Society of Australasia, Newcastle (2005) [E3]
Co-authorsPaul Tooney, Pat Michie, Juanita Todd, Ulrich Schall, Rodney Scott, Judith Weidenhofer
2004Bowden NA, Weidenhofer JC, Scott R, Todd J, Case V, Schall UA, Tooney PA, 'Altered Expression of Brain Related Genes in Lymphocytes in Schizophrenia', American Journal of Medical Genetics, Ireland (2004) [E3]
DOI10.1002/ajmg.b.30101
Co-authorsJudith Weidenhofer, Ulrich Schall, Juanita Todd, Rodney Scott, Paul Tooney
2004Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Gene Profiling in the Amygdala in Schizophrenia', American Journal of Medical Genetics, Ireland (2004) [E3]
Co-authorsJudith Weidenhofer, Rodney Scott, Paul Tooney
2004Bowden NA, Weidenhofer JC, Scott R, Todd J, Case V, Schall UA, Tooney PA, 'Differental Gene Expression in Peripheral Blood Lymphocytes in Schizophrenia', Proceedings of the Australian Neuroscience Society, Melbourne (2004) [E3]
Co-authorsRodney Scott, Paul Tooney, Juanita Todd, Ulrich Schall, Judith Weidenhofer
2004Weidenhofer JC, Bowden NA, Scott R, Tooney PA, 'Altered Gene Expression Profiles in the Amygdala in Schizophrenia', Proceedings of the Australian Neuroscience Society, Melbourne (2004) [E3]
Co-authorsJudith Weidenhofer, Paul Tooney, Rodney Scott
2004Bowden NA, Weidenhofer JC, Scott R, Todd J, Case V, Schall UA, Tooney PA, 'Distinct Gene Expression Profiles due to Age in Schizophrenia', Proceedings of the Australian Neuroscience Society, Melbourne (2004) [E3]
Co-authorsJuanita Todd, Rodney Scott, Paul Tooney, Judith Weidenhofer, Ulrich Schall
Show 69 more conferences
Edit

Grants and Funding

Summary

Number of grants23
Total funding$1,998,691

Click on a grant title below to expand the full details for that specific grant.


20153 grants / $660,500

Investigation of the DNA repair protein XPC in melanoma treatment resistance.$600,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamDoctor Nikola Bowden
SchemeCareer Development Fellowship
RoleLead
Funding Start2015
Funding Finish2015
GNoG1400706
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Destroying kidney cells that evade current treatments$46,000

Funding body: Kidney Health Australia

Funding bodyKidney Health Australia
Project TeamDoctor Craig Gedye, Doctor Nikola Bowden, Professor Rodney Scott
SchemeMedical Research Project Grants
RoleInvestigator
Funding Start2015
Funding Finish2015
GNoG1401048
Type Of FundingAust Competitive - Non Commonwealth
Category1NS
UONY

Too Much of a Good Thing: Application for a triple-gas incubator to allow cell culture under normal conditions$14,500

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Craig Gedye, Professor Rodney Scott, Doctor Nikola Bowden, Doctor Simon Keely, Doctor Kathryn Skelding
SchemeResearch Grant
RoleInvestigator
Funding Start2015
Funding Finish2015
GNoG1500730
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20132 grants / $391,870

Investigation of the nucleotide excision repair pathway for melanoma biomarkers. $199,782

Funding body: Cancer Australia

Funding bodyCancer Australia
Project TeamDoctor Nikola Bowden
SchemeProject Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1200391
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

Development of a chemotherapy response/resistance test for ovarian cancer$192,088

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikola Bowden
SchemeProject Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1300897
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20125 grants / $133,855

Research Equipment$54,355

Funding body: Hunter Melanoma Foundation

Funding bodyHunter Melanoma Foundation
Project TeamDoctor Nikola Bowden
SchemeResearch Equipment Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200936
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Development of a diagnostic genetic test for childhood skin cancer disorders$40,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikola Bowden, Professor Rodney Scott
SchemeResearch Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200164
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Development of a diagnostic test for Xeroderma Pigmentosum , Cockayne’s Syndrome and Trichothiodystrophy$17,500

Funding body: The Marian & E. H. Flack Trust

Funding bodyThe Marian & E. H. Flack Trust
Project TeamDoctor Nikola Bowden
SchemeResearch Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1300524
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Emerging Research Leaders Program 2011$15,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Nikola Bowden
SchemeEmerging Research Leaders Program
RoleLead
Funding Start2012
Funding Finish2012
GNoG1101040
Type Of FundingInternal
CategoryINTE
UONY

Rotary Club of Cardiff Melanoma Scholar Award$7,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikola Bowden
SchemeProject Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200831
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20111 grants / $35,000

Nucleotide excision repair gene expression in melanoma$35,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikola Bowden, Doctor Katie Ashton, Doctor Stephen Braye, Professor Rodney Scott, Dr Ricardo Vilain
SchemeProject Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1001057
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20102 grants / $91,975

Altered nucleotide excision repair in melanoma in response to cisplatin and UV-light irradiation$90,000

Funding body: Cancer Australia

Funding bodyCancer Australia
Project TeamDoctor Nikola Bowden
SchemePriority-driven Collaborative Cancer Research Scheme
RoleLead
Funding Start2010
Funding Finish2010
GNoG0190317
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

101st American Association of Cancer Research Annual Meeting, Convention Centre, Washington DC, USA, 17 - 21st April 2010$1,975

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding bodyUniversity of Newcastle - Faculty of Health and Medicine
Project TeamDoctor Nikola Bowden
SchemeTravel Grant
RoleLead
Funding Start2010
Funding Finish2010
GNoG1000132
Type Of FundingInternal
CategoryINTE
UONY

20093 grants / $518,921

Molecular mechanisms of UV-light induced skin malignancies$333,921

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamDoctor Nikola Bowden
SchemeEarly Career Fellowships
RoleLead
Funding Start2009
Funding Finish2009
GNoG0189304
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Genome wide SNP associated study of childhood acute lymphoblastic leukaemia$140,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Rodney Scott, Doctor Nikola Bowden, Doctor Bente Talseth-Palmer
SchemePaediatric Oncology Project Grant
RoleInvestigator
Funding Start2009
Funding Finish2009
GNoG0189790
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Gene expression profiling of Xeroderma pigmentosum$45,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Rodney Scott, Doctor Nikola Bowden, Doctor Katie Ashton
SchemePostdoctoral Fellowship
RoleInvestigator
Funding Start2009
Funding Finish2009
GNoG0900194
Type Of FundingDonation - Aust Non Government
Category3AFD
UONY

20083 grants / $121,730

Gene expression profiling of xeroderma pigmentosum$100,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Rodney Scott, Doctor Nikola Bowden
SchemePostdoctoral Fellowship
RoleInvestigator
Funding Start2008
Funding Finish2008
GNoG0188353
Type Of FundingDonation - Aust Non Government
Category3AFD
UONY

Genome wide SNP association study of childhood acute lymphoblastic leukaemia$20,000

Funding body: Hunter Children`s Research Foundation

Funding bodyHunter Children`s Research Foundation
Project TeamDoctor Nikola Bowden, Professor Rodney Scott, Doctor Bente Talseth-Palmer
SchemePaediatric Oncology Project Grant
RoleLead
Funding Start2008
Funding Finish2008
GNoG0188483
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Australian health & meidcal Research Congress, Brisbane Convention Centre, 16/11/2008 - 21/11/2008$1,730

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Nikola Bowden
SchemeTravel Grant
RoleLead
Funding Start2008
Funding Finish2008
GNoG0189663
Type Of FundingInternal
CategoryINTE
UONY

20073 grants / $33,000

Gene expression profiling of xeroderma pigmentosum$20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikola Bowden, Professor Rodney Scott
SchemeProject Grant
RoleLead
Funding Start2007
Funding Finish2007
GNoG0187261
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Identification of a predictive approach to assigning to undefined xeroderma pigmentosum patients to subgroups using gene expression profiling$10,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikola Bowden
SchemeProject Grant
RoleLead
Funding Start2007
Funding Finish2007
GNoG0187256
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Travel prize to attend: 4th Annual Illumina User Meeting (March '08) and American Association for Cancer Research (AACR) 99th Annual Meeting (April 12-16 '08)$3,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikola Bowden
SchemePULSE Education Prize
RoleLead
Funding Start2007
Funding Finish2007
GNoG0187298
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20061 grants / $11,840

Gene Expression Profiling of Xeroderma Pigmentosum$11,840

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Nikola Bowden
SchemeEarly Career Researcher Grant
RoleLead
Funding Start2006
Funding Finish2006
GNoG0186964
Type Of FundingInternal
CategoryINTE
UONY
Edit

Research Supervision

Current Supervision

CommencedResearch Title / Program / Supervisor Type
2015Nucleotide Excision Repair of UVA-Induced DNA Damage: Regulation in Sunlight-Induced Melanoma
Health, Faculty of Health and Medicine
Principal Supervisor
2013Nucleotide Excision Repair and UVB-Induced DNA Damage in Melanoma Development
Health, Faculty of Health and Medicine
Principal Supervisor
2013Expression of the Uncharacterised BCL-2 Isoform, BCL2-B in Melanoma
Health, Faculty of Health and Medicine
Principal Supervisor
2012Examining Nucleotide Excision Repair Genes in Melanoma
Health, Faculty of Health and Medicine
Principal Supervisor
2010Role of Tandem Repeats in Genetic Susceptibility to Breast Cancer
Health, Faculty of Health and Medicine
Co-Supervisor

Past Supervision

YearResearch Title / Program / Supervisor Type
2014The Contribution of Genetic Susceptibility to Breast Cancer
Health, Faculty of Health and Medicine
Co-Supervisor
2013The Complex Genetics of Multiple Sclerosis
Health, Faculty of Health and Medicine
Co-Supervisor
Edit

News

DNA protein targeted in ovarian cancer

DNA protein targeted in ovarian cancer chemo test DNA protein targeted in ovarian cancer chemo test

February 25, 2015

University of Newcastle researcher Dr Nikola Bowden is investigating a DNA repair protein that is implicated in ovarian cancer tumours becoming resistant to chemotherapy, with hopes of eventually developing a prognostic test and more tailored treatments.

Dr Nikola Bowden

Position

Research Fellow
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Medical Genetics

Contact Details

Emailnikola.bowden@newcastle.edu.au
Phone(02) 40420277
Fax02 40420031

Office

RoomHMRI Level 3 West
BuildingHMRI
LocationHMRI

,
Edit